Table 8.
Overview of sensitivity analyses of most cost effective vaccination strategy (direct costs) by country, vaccine availability, and immunity scenario
| Vaccination strategy | Germany | Netherlands | United Kingdom | |||||
|---|---|---|---|---|---|---|---|---|
| No immunity | Pre-existing immunity | No immunity | Pre-existing immunity | No immunity | Pre-existing immunity | |||
| High vaccine cost: | ||||||||
| Early vaccination | Elderly people | High transmitters | High transmitters | High transmitters | High transmitters | High transmitters | ||
| Late vaccination | Elderly people | High transmitters | Elderly people | High transmitters | Elderly people | High transmitters | ||
| No discounting: | ||||||||
| Early vaccination | Elderly people | High transmitters | High transmitters | High transmitters | High transmitters | High transmitters | ||
| Late vaccination | Elderly people | High transmitters | Elderly | High transmitters | Elderly people | High transmitters | ||
| High transmissibility: | ||||||||
| Early vaccination | Elderly people | High transmitters | High transmitters | High transmitters | High transmitters | High transmitters | ||
| Late vaccination | Elderly people | Elderly people | Elderly people | Elderly people | Elderly people | Elderly people | ||
| Low transmissibility: | ||||||||
| Early vaccination | High transmitters | High transmitters | High transmitters | High transmitters | High transmitters* | High transmitters* | ||
| Late vaccination | Elderly people | High transmitters | Elderly people | High transmitters | Elderly people | High transmitters | ||
| Low vaccination coverage: | ||||||||
| Early vaccination | Whole population | High transmitters | High transmitters | High transmitters | High transmitters | High transmitters | ||
| Late vaccination | Elderly people | High transmitters | Elderly people | High transmitters | Elderly people | High transmitters | ||
| High pre-existing immunity: | ||||||||
| Early vaccination | NA | High transmitters | NA | High transmitters | NA | High transmitters | ||
| Late vaccination | NA | High transmitters | NA | High transmitters | NA | High transmitters | ||
NA=not applicable.
Assumptions underlying sensitivity analyses are given in the methods. Supplementary tables A.4 to A.6 show the full sensitive results, including interactions between factors, incremental cost effectiveness ratios, and scenarios with indirect costs. Cost effectiveness is calculated excluding indirect costs. Scenarios are: vaccination of whole population, vaccination of elderly people, and vaccination of high transmitters—all compared with no vaccination. See table 2 for overview of scenarios.
*Cost saving strategy.